Introduction
Refractory status epilepticus (RSE) is defined as status epilepticus (SE) unresponsive to an application of at least two properly dosed antiepileptic drugs (AEDs). Guidelines advocate a use of anesthetics as third-line therapy in refractory generalizedconvulsive status epilepticus (GCSE) and refractory nonconvulsive status epilepticus (NCSE) in coma. The risks of such an approach are thought to potentially outweigh its benefits in refractory complex-partial SE (CPSE) and, therefore, a higher number of different intravenously or orally administered non-anesthetic AEDs are frequently tried first in these cases [1, 2] . Among the later-line oral AED options is topiramate (TPM), which has repeatedly been linked to successful RSE termination in case series over the last years [3] [4] [5] [6] . As the data is still very limited, we examined a large cohort of RSE episodes in order to assess factors associated with the use of TPM in RSE.
Methods

RSE episodes and data collection
In accordance with previously published studies, status epilepticus (SE) was defined as ongoing clinical and/or electroencephalographic seizure activity for at least 5 min or as a series of seizures without interictal clinical recovery. RSE was defined as SE in which two adequately dosed AEDs failed to terminate seizures. SE cases treated in our institution between January 2001 and January 2013 were identified through query of our electronic medical record system. We reviewed the medical charts of all these cases and included those into the study which met the diagnostic criteria for RSE mentioned above. Where necessary, EEGs were reviewed as part of this process. Medical charts were used to collect data on baseline demographics, RSE characteristics, RSE treatment, and complications during hospital stay. RSE duration was defined as time from the onset of seizures until clear clinical and/or EEG evidence of seizure cessation. For reasons of comparability with previous studies, we excluded RSE caused by hypoxic encephalopathy as well as simple-partial and absence RSE episodes. RSE etiology was classified as proposed by the ILAE (cryptogenic or acute, remote, or progressive symptomatic) [7] . The definition of potentially fatal etiology was adopted from Rossetti and coworkers [8] . RSE severity was graded with the Status Epilepticus Severity Score (STESS) using the previously proposed dichotomization into STESS !3 or less (STESS <3) [9] . Regarding TPM therapy, the date of first application, the dose administered within the first 24 h, the speed of dose increase, as well as the maximum TPM dose were extracted. The study was approved by the local institutional review board (Ethics Committee Vote: 48_15Bc).
Outcome measures and functional outcome assessment
The study's outcome measures were successful RSE termination during hospital stay, in-hospital mortality, and functional longterm outcome. Functional long-term outcome was assessed with the modified Rankin Scale based on the last documented follow-up in our files. We defined that good functional long-term outcome could be achieved in two ways: (1) a return to the premorbid mRS (=back to baseline), or (2) in case of increase in the mRS: a final mRS of 2 or lower. Otherwise, outcome was defined as poor.
Statistics
Variables were compared between episodes with (=+TPM) and without TPM treatment (=ÀTPM) in the entire cohort and in subgroups defined by seizure type (complex-partial vs. generalized convulsive and nonconvulsive SE in coma). [10] after exclusion of multicollinearity. In case of multicollinearity, only the variable with the lowest p value was included into the model. The multivariate analyses were performed using software available online at http://www.wessa.net. We used SPSS Statistics 21.0 (http://www.spss.com) for all other calculations.
Results
Among 445 SE episodes treated for SE in the above mentioned period, we identified 71 RSE episodes in 65 patients which fulfilled the criteria for inclusion into this study. In 17/71 (23.9%) episodes, patients received TPM for the treatment of RSE. The median starting dose was 100 mg/day (IQR, 50-400 mg/day) and the median maximum dose was 225 mg/day (IQR, 150-1000 mg/day). In none of the episodes a loading dose was administered. In 12/17 (70.6%) episodes, a daily TPM dose of at least 100 mg was prescribed within the first two days of TPM therapy, in 6/17 (35.3%) episodes the starting dose was 400 mg/day or more. TPM was applied as median 7th-line AED (IQR, 5th-9th) and a median of 2 more AEDs (IQR, 0-4) were necessary for seizure control. In 5/17 (29.4%) episodes, TPM was the last AED added to therapy before seizure termination. In only one of these cases, the end of seizures was diagnosed within 72 h after initiation of TPM therapy; however, there were changes in concomitant AEDs during that time. Table 1 provides a summary of the univariate comparisons of episodes treated with and without TPM. Patients were significantly younger in episodes treated with TPM and there was a trend toward a lower premorbid mRS. Regarding RSE severity, TPM was more frequently used in episodes with significantly lower STESS. Treatment with TPM was associated with a higher overall number of AEDs applied and longer RSE duration, whereas the use of anesthetics was not significantly more frequent in these episodes. While functional outcome showed no differences between +TPM and ÀTPM episodes in the overall cohort, the chance of RSE termination appeared significantly higher when TPM was part of the AED regimen.
Univariate analysis
Subgroup analysis revealed marked differences between the +TPM and ÀTPM cohorts in complex-partial RSE episodes. Regarding baseline variables, the +TPM subgroup was characterized by significantly younger age, lower premorbid mRS, and lower median STESS. RSE duration was significantly longer, a higher number of AEDs were applied, and anesthetics were more frequently part of the therapeutic regimen (see Table 2 ). In more episodes vasopressors had to be prescribed and sepsis was more common. There appeared to be a trend toward higher chance of successful seizure termination, whereas in-hospital mortality and outcome at follow-up did not differ significantly between groups.
Regarding the subgroup of generalized convulsive RSE and refractory NCSE in coma, the only significant difference between the +TPM and ÀTPM cohorts was longer RSE duration when TPM was part of the therapeutic regimen. Furthermore, there was a trend toward a use of a higher number of AEDs.
Multivariate analysis
Based on the results of the univariate analysis and after testing for multicollinearity, the following variables were included into multivariate models to assess factors associated with the use TPM in the overall cohort and in the subgroup of complex-partial RSE: age, premorbid mRS, number of AEDs applied, and RSE duration. None of the variables turned out to be independently associated with the use of TPM (Table 3a) . Similarly, the significance of the association of the use of TPM with successful RSE termination in the overall cohort was lost once corrected for age, i.e. the only other variable linked to a higher chance for successful RSE treatment in univariate analysis (RSE terminated: 68 (IQR, 48-74) vs. RSE not terminated: 77 (IQR, 68-90); p = 0.008; Table 3b ).
Discussion
In this study, we retrospectively analyzed RSE episodes in an attempt (1) to identify factors associated with the use of TPM and (2) to assess evidence for a particular efficacy of TPM in RSE termination. In the interpretation of our results, several aspects deserve attention.
The univariate analysis suggests evidence for clear differences between episodes treated with and without TPM regarding baseline characteristics, the clinical course, and the chance for successful RSE termination. It appears that TPM was primarily applied in younger and healthier patients as part of a more aggressive and perseverant therapeutic approach as indicated by the higher number of AEDs applied; the combination of these factors could serve as an explanation for the seemingly higher RSE termination rate in the +TPM cohort. The subgroup analysis on the seizure type probably most suitable for assessing a potential efficacy of a late-line therapeutic option like TPM, i.e. complexpartial RSE, seems to further corroborate these findings. In a multivariate model adjusting for RSE duration, however, neither Abbreviations: AED = antiepileptic drug; mRS = modified Rankin Scale; RSE = refractory status epilepticus; parameters showing a statistical trend are expressed in italics. differences in baseline characteristics nor number of AEDs remained statistically significant in neither the overall cohort nor the subgroup of complex-partial RSE. In sum, we could not identify any significant differences between episodes treated with and without TPM and we, moreover, found no evidence for TPM being an independent predictor of successful RSE termination. RSE is a heterogeneous and complex condition, in which both outcome and therapy are determined by a multitude of interacting factors. Our study demonstrates how easily use of inappropriate statistical tools can lead to false conclusions not in actuality supported by the data, particularly in retrospective studies where there is no opportunity to control for confounders at baseline.
Comparing our results with those of previous studies on the use of TPM in RSE is difficult as the latter mainly put their focus on characterizing the differences between TPM responders and nonresponders, and were largely descriptive, with only one attempting statistical comparisons [4] , of note also with a univariate approach. Moreover, the median maximum TPM dose prescribed was relatively low in our study [4] [5] [6] . Of note, when we applied criteria comparable to those used in the aforementioned studies requiring RSE termination to occur within a maximum of 72 h after TPM initiation without any change in concomitant AEDs during that time, no definite TPM responders could be identified in our cohort. In our experience, however, precisely assessing the exact time of seizure cessation retrospectively in episodes of extreme RSE duration is difficult as EEGs may be performed less regularly over time and the documentation of the clinical findings may be too imprecise to allow for clear discrimination between the late ictal and early postictal phase. Therefore, we deliberately chose a different approach trying to assess a potential TPM efficacy by comparing RSE episodes with regards to whether TPM was part of the regimen at all or not. Jacques and Rossetti in their study proceeded similarly [11] , however, they did not focus on TPM exclusively, but on newer AEDs in general. Their cohort included 9 cases in which TPM was applied, but these were neither characterized in detail nor compared with episodes not treated with TPM. Regarding further studies, we can compare parts of our findings with those of Synowiec and coworkers who reported an RSE termination rate of 100% in 35 episodes treated with TPM sometime during RSE. Again, these episodes were not compared with others in which TPM was not part of the regimen [4] .
We are aware that this purely exploratory study has several limitations, one being the above described method applied for assessing TPM efficacy. Besides methodological considerations, the rationale for this approach was that TPM is considered a broad spectrum AED with multiple modes of action thought to potentially act synergistically with those of other co-administered AEDs [3] . In addition to a direct potential to abort seizures it may thus contribute to RSE termination indirectly. Although limited, our results do not yield any evidence for such an effect. However, our sample size was small and this limitation is mirrored by some wide confidence intervals in our multivariate models. Our results, therefore, need confirmation by studies with larger numbers of RSE episodes.
